Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension (2015)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1093/eurheartj/eht549
- Subjects: EVENTO ADVERSOS A MEDICAMENTOS; FÁRMACOS (SISTEMA CARDIOVASCULAR); HIPERCOLESTEROLEMIA (TERAPIA)
- Language: Inglês
- Imprenta:
- Source:
- Título: European heart journal
- ISSN: 0195-668X
- Volume/Número/Paginação/Ano: v. 36, n. 9, p. 566-575, 2015
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SANTOS, Raul D. et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. European heart journal, v. 36, n. 9, p. 566-575, 2015Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/eht549. Acesso em: 26 jan. 2026. -
APA
Santos, R. D., Duell, P. B., East, C., Guyton, J. R., Moriarty, P. M., Chin, W., & Mittleman, R. S. (2015). Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. European heart journal, 36( 9), 566-575. doi:10.1093/eurheartj/eht549 -
NLM
Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension [Internet]. European heart journal. 2015 ; 36( 9): 566-575.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1093/eurheartj/eht549 -
Vancouver
Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension [Internet]. European heart journal. 2015 ; 36( 9): 566-575.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1093/eurheartj/eht549 - Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
- Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study
- Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia
- Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study
- Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients
- Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia
- Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications?
- Sodium intake and prevalence of hypertension in elementary school students
- Clinical Genetic Testing for Familial Hypercholesterolemia
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab
Informações sobre o DOI: 10.1093/eurheartj/eht549 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
